ESR1 and neoplasm: In these preclinical experiments performed on an ERα-positive tumor model (MCF7-Y537S), we show that FES-PET can be used as a pharmacodynamic imaging biomarker to demonstrate ER target engagement and map impact of SAR439859 SERD.